This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > About EXJADE > EXJADE vs Deferoxamine (DFO)
Print

In this section:

EU SmPC

Only EXJADE offers once-daily oral chelation

What is typical compliance for a patient taking DFO?
EXJADE Desferal
Mix and drink solution once a day on an empty stomach, preferably at the same time each day.

Learn more

 ROUTE OF ADMINISTRATION MUST BE CHOSEN ON AN INDIVIDUAL BASIS

Subcutaneous with infusion pump
  • Administer 20-60 mg/kg/day over a period of 8-12 hours 5-7 times a week
Intramuscular injection
  • Administer 1000 mg/day by intramuscular injection for a child
  • Administer 2000 mg by intramuscular injection for an adult
  • The rate of intravenous infusion must not exceed 80 mg/kg/hr in any 24 hour period
Exjade vs. Deferoxamine: Patient Compliance

EXJADE FAQ

Find answers to all of
your EXJADE questions.

Learn more

SAFETY PROFILE
ACROSS ANEMIAS



Learn more

References

  1. EXJADE® summary of product characteristics. West Sussex, United Kingdom: Novartis Europharm Limited; 2011.
  2. Desferal® Summary of Product Characteristics. United Kingdom; Novartis Pharma 2010.
TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with β-thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusion in patients aged 2 years and older with β-thalassemia major or other anemias when deferoxamine is contraindicated or inadequate.
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed